Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenita...
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG
About this item
Full title
Author / Creator
Publisher
England: The Company of Biologists Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: The Company of Biologists Ltd
Subjects
More information
Scope and Contents
Contents
Phosphomannomutase 2 deficiency, or PMM2-CDG, is the most common congenital disorder of glycosylation and affects over 1000 patients globally. There are no approved drugs that treat the symptoms or root cause of PMM2-CDG. To identify clinically actionable compounds that boost human PMM2 enzyme function, we performed a multispecies drug repurposing...
Alternative Titles
Full title
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_73f5388e14c348678bb225c904595475
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_73f5388e14c348678bb225c904595475
Other Identifiers
ISSN
1754-8403
E-ISSN
1754-8411
DOI
10.1242/dmm.040584
